Unraveling the Crosstalk between Lipids and NADPH Oxidases in Diabetic Kidney Disease
Pharmaceutics · 28.04.2023 · 15 (5) · 1360
DOI: 10.3390/pharmaceutics15051360 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 28.04.2023. Verfasst von Rachel Njeim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL 33136, USA. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 187 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, National Institutes of Health, Miami Clinical Translational Science Institute.
Abstract (Originalsprache)
Diabetic kidney disease (DKD) is a serious complication of diabetes mellitus and a leading cause of end-stage renal disease. Abnormal lipid metabolism and intrarenal accumulation of lipids have been shown to be strongly correlated with the development and progression of diabetic kidney disease (DKD). Cholesterol, phospholipids, triglycerides, fatty acids, and sphingolipids are among the lipids that are altered in DKD, and their renal accumulation has been linked to the pathogenesis of the disease. In addition, NADPH oxidase-induced production of reactive oxygen species (ROS) plays a critical role in the development of DKD. Several types of lipids have been found to be tightly linked to NADPH oxidase-induced ROS production. This review aims to explore the interplay between lipids and NADPH oxidases in order to provide new insights into the pathogenesis of DKD and identify more effective targeted therapies for the disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
- Peggy and Harold Katz Family Drug Discovery Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
- Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut 1107-2020, Lebanon.
- AUB Diabetes, American University of Beirut, Beirut 1107-2020, Lebanon.
Förderung
- NIH HHS
- National Institutes of Health
- Miami Clinical Translational Science Institute
- L’Oréal UNESCO for Women in Science Levant Regional Young Talents grant
Zitieren
APA
Njeim, R., Alkhansa, S., & Fornoni, A. (2023). Unraveling the Crosstalk between Lipids and NADPH Oxidases in Diabetic Kidney Disease. Pharmaceutics, 15(5), 1360. https://doi.org/10.3390/pharmaceutics15051360
Vancouver
Njeim R, Alkhansa S, Fornoni A. Unraveling the Crosstalk between Lipids and NADPH Oxidases in Diabetic Kidney Disease. Pharmaceutics. 2023;15(5):1360. doi:10.3390/pharmaceutics15051360
BibTeX
@article{Njeim2023,
author = {Njeim, Rachel and Alkhansa, Sahar and Fornoni, Alessia},
title = {Unraveling the Crosstalk between Lipids and NADPH Oxidases in Diabetic Kidney Disease},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {5},
pages = {1360},
doi = {10.3390/pharmaceutics15051360}
}
EUVIMED